Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects.
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2012 Results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
- 01 Mar 2012 Results published in the Osteoporosis International.
- 01 Nov 2007 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History